<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256086</url>
  </required_header>
  <id_info>
    <org_study_id>D-64428-3278</org_study_id>
    <secondary_id>IND #101,246</secondary_id>
    <nct_id>NCT01256086</nct_id>
  </id_info>
  <brief_title>Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg</brief_title>
  <official_title>Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg in Patients With Stable Asthma Using Bronchoprovocation With Methacholine as a Bioassay Randomized, Double-blind, Four-period, Four-sequence Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinResearch, GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trio Clinical Research, LLC, Raleigh, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NuCara Pharmacy, Waterloo, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prof. Hochhaus, Gainesville, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the relative potency for bronchoprotective effect of
      formoterol Novolizer 12 µg (test) compared to formoterol Aerolizer 12 µg (reference).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PC20 = Provocation Concentration of Methacholine That Cause a 20% Decrease in Forced Expiratory Volume in the First Second (FEV1)</measure>
    <time_frame>60 min after application of study medication</time_frame>
    <description>The primary variable is the methacholine PC20 after inhalation of study medication; the PC20 is the concentration of methacholine that - despite protection by study medication - causes a 20% fall in FEV1 compared to the pre-methacholine (post-saline) level of the given study day.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>24 µg Formoterol Novolizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12µg Formoterol Novolizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 µg Formoterol Aerolizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12µg Formoterol Aerolizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formatris 24µg</intervention_name>
    <description>12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2</description>
    <arm_group_label>24 µg Formoterol Novolizer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formatris 12µg</intervention_name>
    <description>12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2</description>
    <arm_group_label>12µg Formoterol Novolizer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foradil P 24µg</intervention_name>
    <description>Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2</description>
    <arm_group_label>24 µg Formoterol Aerolizer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foradil P 12µg</intervention_name>
    <description>Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2</description>
    <arm_group_label>12µg Formoterol Aerolizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged from 18 to 60 years (inclusive).

          2. Patients with asthma indicated by

               -  history of asthma symptoms and

               -  airway hyperresponsiveness to methacholine with a provocation concentration of
                  methacholine that cause a 20% decrease in FEV1 (PC20) ≤8 mg/ml at Visit 1.

          3. Patients with stable asthma condition with baseline forced expiratory volume in the
             first second (FEV1) ≥70% predicted at first visit.

          4. The PC20 methacholine should increase at least 4-fold after inhaling 24 μg of
             formoterol Aerolizer (2 applications of 12 μg) at Visit 2.

          5. Able to be taught correct inhalation technique for both devices at screening.

        Exclusion Criteria:

          1. Known hypersensitivity to formoterol, lactose, or methacholine.

          2. History of life-threatening asthma in the last three years.

          3. Major malignancies including pheochromocytoma within the last 5 years. Exception will
             be considered where malignancies have been resolved as judged by investigator.

          4. Pregnancy, breast-feeding, planned pregnancy during the study, or women of
             child-bearing potential not using adequate contraception. These methods include total
             abstinence (no sexual intercourse), oral contraceptives, an intrauterine device (IUD),
             an etonogestrel implant (Implanon), or medroxyprogesterone acetate injections
             (Depo-Provera shots). If one of these cannot be used, using contraceptive foam and a
             condom are recommended.

             Lack of suitability for the study:

          5. Screening visit 2 has to be postponed repeatedly.

          6. Evidence of respiratory tract infection within 4 weeks before the study (screening
             visit 1).

          7. Seasonal or episodic exposure to an allergen or occupational chemical sensitizer which
             are likely to vary in symptom presentation and severity during the course of the study
             (e.g. ragweed sensitive patients in Iowa during Aug-Oct). This does not apply to
             patients who can be well controlled on therapy.

          8. History of non-reversible pulmonary disease; chronic obstructive pulmonary disease
             (COPD), cystic fibrosis, bronchiectasis, or pulmonary fibrosis.

          9. History of severe cardiovascular, renal, neurologic, liver or endocrine dysfunction
             (patients with well-controlled hypertension, hypercholesterolemia, thyroid disease or
             diabetes may be included if medication for these diseases does not affect methacholine
             challenge or formoterol metabolism).

         10. History of hemophilia or coagulation disease.

         11. Electrocardiogram (ECG) abnormalities of clinical relevance, in particular abnormal
             prolongation of QT-interval (QTc according to Bazett in women ≥450 msec, in men ≥430
             msec).

         12. Potassium level below lower limit of laboratory normal range plus 0.3 mmol/l as safety
             margin.

         13. Exacerbation of bronchial asthma requiring emergency department visit or
             hospitalization during the last 3 months prior to this study.

         14. Prior or concomitant treatment with systemic glucocorticosteroids during the last 3
             months (a short course of oral corticosteroids for asthma is permissible if for &lt;10
             days and at least 30 days have passed).

         15. Use of long-acting ß2-agonists in last 3 weeks before the first methacholine challenge
             or during the study

         16. Change in dosage of other controller therapy (inhaled glucocorticosteroids,
             leukotriene modifier, slow-release theophylline) during the last 3 weeks before the
             first methacholine challenge or during the study.

         17. Use of short-acting ß2-agonists more than thrice a week in the previous month.

         18. Inability to temporary withhold the following medications/substances before lung
             function test:

               -  short-acting ß2-agonists and short-acting anticholinergics at least 6 hours,

               -  regular long-acting ß2-agonists at least 3 weeks,

               -  long-acting anticholinergics at least 36 hours,

               -  inhaled glucocorticosteroids at least 2 hours

               -  Disodium cromoglycate (DSCG) at least 24 hours,

               -  slow release theophylline at least 48 hours,

               -  rapid release theophylline at least 24 hours,

               -  caffeine at least 4 hours

         19. Patients with aspirin induced bronchospasm.

         20. Any treatment with ß2-antagonists (including eye drops).

         21. Non-cooperative patients, inability to perform outcome measurement correctly.

         22. Inability to measure PC20 methacholine after 24 μg of formoterol Aerolizer (PC20 &gt;128
             mg/ml).

         23. Current smokers or regular smokers during last 12 months or more than 10 pack-year
             history.

         24. Drug or alcohol abuse which would interfere with the patient's proper completion of
             the protocol assignment.

             Administrative reasons:

         25. Participation in another clinical study within 1 month prior to or during this study

         26. Lack of ability or willingness to give informed consent.

         27. Lack of willingness to have personal study related data collected, archived or
             transmitted according to protocol.

         28. Personnel involved in the planning or conduct of the study.

         29. Anticipated non-availability for study visits/procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Hendeles, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida, Gainesville, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32160-0486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <results_first_submitted>July 26, 2012</results_first_submitted>
  <results_first_submitted_qc>August 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2012</results_first_posted>
  <last_update_submitted>August 13, 2012</last_update_submitted>
  <last_update_submitted_qc>August 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient was enrolled in December 2010, last patient completed in July 2011</recruitment_details>
      <pre_assignment_details>During screening phase (within 14 days before but at latest 2 days before randomisation), 2 methacholine tests on separate days (with and without pre-medication) were performed to check the suitability of the patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>N1A2A1N2</title>
          <description>Treatment sequence 12 µg Novolizer - 24 µg Aerolizer - 12 µg Aerolizer - 24 µg Novolizer</description>
        </group>
        <group group_id="P2">
          <title>A1N1N2A2</title>
          <description>Treatment sequence 12 µg Aerolizer - 12 µg Novolizer - 24 µg Novolizer - 24 µg Aerolizer</description>
        </group>
        <group group_id="P3">
          <title>N2A1A2N1</title>
          <description>Treatment sequence 24 µg Novolizer - 12 µg Aerolizer - 24 µg Aerolizer - 12 µg Novolizer</description>
        </group>
        <group group_id="P4">
          <title>A2N2N1A1</title>
          <description>Treatment sequence 24 µg Aerolizer - 24 µg Novolizer - 12 µg Novolizer - 12 µg Aerolizer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Day 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Day 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Day 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Day 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N1A2A1N2</title>
          <description>Sequence 1: N1A2A1N2 (Treatment day 1 to treatment day 4) N1 = 12µg Novolizer N2 = 24µg Novolizer A1 = 12µg Aerolizer A2 = 24µg Aerolizer</description>
        </group>
        <group group_id="B2">
          <title>A1N1N2A2</title>
          <description>Sequence 2: A1N1N2A2 (Treatment day 1 to treatment day 4) N1 = 12µg Novolizer N2 = 24µg Novolizer A1 = 12µg Aerolizer A2 = 24µg Aerolizer</description>
        </group>
        <group group_id="B3">
          <title>N2A1A2N1</title>
          <description>Sequence 3: N2A1A2N1 (Treatment day 1 to treatment day 4) N1 = 12µg Novolizer N2 = 24µg Novolizer A1 = 12µg Aerolizer A2 = 24µg Aerolizer</description>
        </group>
        <group group_id="B4">
          <title>A2N2N1A1</title>
          <description>Sequence 4: A2N2N1A1 (Treatment day 1 to treatment day 4) N1 = 12µg Novolizer N2 = 24µg Novolizer A1 = 12µg Aerolizer A2 = 24µg Aerolizer</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="12"/>
                    <measurement group_id="B2" value="35" spread="13"/>
                    <measurement group_id="B3" value="26" spread="10"/>
                    <measurement group_id="B4" value="28" spread="11"/>
                    <measurement group_id="B5" value="30" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PC20 = Provocation Concentration of Methacholine That Cause a 20% Decrease in Forced Expiratory Volume in the First Second (FEV1)</title>
        <description>The primary variable is the methacholine PC20 after inhalation of study medication; the PC20 is the concentration of methacholine that - despite protection by study medication - causes a 20% fall in FEV1 compared to the pre-methacholine (post-saline) level of the given study day.</description>
        <time_frame>60 min after application of study medication</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>24 µg Formoterol Novolizer</title>
            <description>12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2</description>
          </group>
          <group group_id="O2">
            <title>12µg Formoterol Novolizer</title>
            <description>12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2</description>
          </group>
          <group group_id="O3">
            <title>24 µg Formoterol Aerolizer</title>
            <description>Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2</description>
          </group>
          <group group_id="O4">
            <title>12µg Formoterol Aerolizer</title>
            <description>Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2</description>
          </group>
        </group_list>
        <measure>
          <title>PC20 = Provocation Concentration of Methacholine That Cause a 20% Decrease in Forced Expiratory Volume in the First Second (FEV1)</title>
          <description>The primary variable is the methacholine PC20 after inhalation of study medication; the PC20 is the concentration of methacholine that - despite protection by study medication - causes a 20% fall in FEV1 compared to the pre-methacholine (post-saline) level of the given study day.</description>
          <population>Per Protocol Population</population>
          <units>mg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="138.8"/>
                    <measurement group_id="O2" value="20.9" spread="130.1"/>
                    <measurement group_id="O3" value="33.2" spread="96.4"/>
                    <measurement group_id="O4" value="17.8" spread="172.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Relative potency of Novolizer compared to Aerolizer. Equivalence was to be concluded if the CI for the relative potency was completely covered by the interval (0.67, 1.50) according to OIP Guideline.</non_inferiority_desc>
            <param_type>Relative potency</param_type>
            <param_value>1.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>Fieller confidence interval for logarithm of relative potency</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>24 µg Formoterol Novolizer</title>
          <description>12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2</description>
        </group>
        <group group_id="E2">
          <title>12µg Formoterol Novolizer</title>
          <description>12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2</description>
        </group>
        <group group_id="E3">
          <title>24 µg Formoterol Aerolizer</title>
          <description>Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2</description>
        </group>
        <group group_id="E4">
          <title>12µg Formoterol Aerolizer</title>
          <description>Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>laryngeal cancer stage 0</sub_title>
                <description>Squamous cell carcinoma in situ of the left vocal cord was reported in a female patient with an ongoing history of worsening of vocal hoarseness since 2008. This event was assessed as unlikely related to the use of study drug (Aerolizer 12 µg)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <description>allergic reaction to a cat</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>INSTITUTION shall have the right to publish the results of its part of the study either independently or in collaboration with SPONSOR.In either case, INSTITUTION agrees to submit a copy of any manuscript and/or abstract to SPONSOR for review and comment sixty (60) days prior to its submission for publication. SPONSOR shall have said sixty (60) day period to respond to INSTITUTION with any requested revisions. INSTITUTION agrees to delete information identified by SPONSOR as confidential.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Leslie Hendeles</name_or_title>
      <organization>University of Florida, Department of Pharmacotherapy and Tanslational Research, 100486 Gainesville, FL 32610</organization>
      <phone>+1 352 279 ext 6027</phone>
      <email>hendeles@cop.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

